该交易对德国政府而言也意味着一种退出方式。在疫情期间，德国政府购入了 CureVac 公司的股份，目 前持有其 13.3%的股权。根据交易条款，德国政府将获得约 1.63 亿美元的 BioNTech 股票。据 BioNTech 称，德国政府对此次交易持积极态度。 智通财经APP获悉，BioNTech(BNTX.US)同意以约 12.5 亿美元的价格全股票收购前新冠疫苗竞争对手 CureVac(CVAC.US)，这将助力其不断发展的肿瘤学业务。该公司周四表示，CureVac 的投资者每持有 1 股 CureVac 股票，就能获得约 5.46 股 BioNTech 股票。这一价格较 CureVac 周三的收盘价高出 34%。交 易完成后，CureVac 的股东将持有 BioNTech 不少于 4%至 6%的股份。消息公布后，截至发稿，CureVac 股价盘前上涨31.20%。 该协议终结了这两家公司长达数十年的竞争关系，这种竞争在研发新冠疫苗的过程中达到了顶点。在新 冠疫苗的竞赛中，BioNTech通过与辉瑞(PFE.US)合作成功赢得了这场比赛，率先完成研发，从而转型 成为欧洲领先的生物技术公司之一。而Cure ...

Group 1 - The core finding of the research is the identification of unique genetic characteristics of T cell clones that may predict the efficacy of cancer immunotherapy, paving the way for personalized treatment approaches [1][2] - Immunotherapy is recognized as a revolutionary breakthrough in cancer treatment, capable of precisely eliminating cancer cells by activating the immune system, but individual patient differences pose significant challenges to its widespread application [1] - The research involved a meta-analysis of single-cell RNA sequencing and T cell receptor sequencing data from numerous cancer patients who underwent immunotherapy, focusing on the relationship between T cell clone characteristics and the success of the therapy [1] Group 2 - The study revealed that while T cell clones exist in both responsive and non-responsive cancer patients, those in responsive patients exhibit a distinct genetic feature and enhanced immune activity due to immunotherapy [2] - It was determined that activating T cell clones present only within tumors, rather than those found in both tumors and blood, is crucial for improving the effectiveness of immunotherapy in treating cancer [2] - This research provides significant insights into the dynamic mechanisms of the human immune system in the cancer fighting process, as published in the latest issue of the journal "Cell Genomics" [2]